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Objectives This study sought to evaluate the interrelation of atherosclerotic burden, as assessed by coronary artery calcium
(CAC) score and coronary vascular function, as assessed by quantitative estimates of coronary flow reserve
(CFR), with respect to prediction of clinical outcomes.
Background The contribution of coronary vascular dysfunction, atherosclerotic burden, and the 2 combined to cardiac events
is unknown.
Method A total of 901 consecutive patients underwent 82Rubidium myocardial perfusion imaging (MPI) positron emis-
sion tomography (PET) and CAC scan. All patients had normal MPI. The primary endpoint was a composite of
major adverse cardiac events (MACE) including cardiac death, nonfatal myocardial infarction, late revasculariza-
tion, and admission for heart failure.
Results At baseline, CFR decreased (2.15  0.72, 2.02  0.65, and 1.88  0.64, p  0.0001) with increasing levels of
CAC (0, 1 to 399, and 400). Over a median of 1.53 years (interquartile range: 0.77 to 2.44), there were 57
MACE. Annual risk-adjusted MACE rates were higher for patients with CFR 2.0 compared with 2.0 (1.9 vs.
5.5%/year, p  0.0007) but were only borderline associated with CAC (3.1%, 3.4%, and 6.2%/year for CAC of 0,
1 to 399, and 400, respectively; p  0.09). Annualized adjusted MACE was increased in the presence of im-
paired CFR even among patients with CAC  0 (1.4% vs. 5.2%, p  0.03). Cox proportional hazards analysis
revealed that CFR improved model fit, risk discrimination, and risk reclassification over clinical risk, whereas
CAC only modestly improved model fit without improving risk discrimination or reclassification.
Conclusions In symptomatic patients with normal MPI, global CFR but not CAC provides significant incremental risk stratifica-
tion over clinical risk score for prediction of major adverse cardiac events. (J Am Coll Cardiol 2013;61:
2098–106) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.02.029Coronary artery calcium (CAC) is absent in normal coro-
nary arteries, whereas its presence and magnitude reflects
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2013, accepted February 19, 2013.the overall burden of coronary atherosclerosis (1,2). Al-
though CAC is a well-established marker of CAD and
clearly risk stratifies asymptomatic subjects (3), the obser-
vation that coronary calcium content is lower in culprit
lesions of patients with acute coronary syndromes compared
to those with stable coronary artery disease (CAD), suggests
that calcification may represent a healing response to injury
(4). However, data from several large prospective studies
demonstrating a stepwise increase in coronary risk with
increasing calcium scores have challenged the notion that
calcified coronary disease represents a scenario of clinical
stability (3,510).
Post-mortem studies have shown that there are many
noncalcified plaques for every calcified plaque (1). Thus, it is
unclear whether CAC itself increases risk of adverse coro-
nary outcomes or whether CAC deposition serves as a proxy
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and its functional consequence of coronary vascular dysfunc-
tion. Our objective was to test the hypothesis that coronary
vascular dysfunction, reflecting the adverse effect of widespread
atherosclerosis on coronary epicardial and microvascular func-
tion, is a key determinant of adverse prognosis irrespective of
the magnitude of coronary artery calcifications.
Methods
Study population and design. A total of 1,240 consecutive
atients underwent both stress myocardial perfusion pos-
tron emission tomography (PET) and CAC computed
omography (CT) at the Brigham & Women’s Hospital
Boston, Massachusetts) between January 9, 2006, and
une 30, 2010, for investigation of symptoms suspicious
f CAD. In order to avoid the confounding effect of
bstructive CAD, patients with abnormal PET myocar-
ial perfusion imaging (MPI) studies (n  292, 23.5%)
ere excluded, as were those with a history of prior
yocardial infarction and/or revascularization (n  78,
.3%), a left ventricular ejection fraction 40% (n  9,
.7%), known valvular heart disease (n  18, 1.5%), or
trial fibrillation (n  0, 0%). The remaining 901 patients
omprised the study cohort for the analysis. The study
as approved by the Partners Healthcare Institutional
eview Board and all study procedures were in accor-
ance with institutional guidelines.
linical and historical data. Clinical histories elicited at
he time of exam ascertained the patients’ symptoms,
oronary risk factors, and medication use at the time of the
ndex study. Height and weight were measured and re-
orded, and body mass index was calculated. The Duke
linical risk score was calculated for each patient as previ-
usly described (11).
ybrid PET/CT study. MYOCARDIAL PERFUSION PET
SCAN. Patients were studied using a whole-body PET-CT
canner (Discovery RX or STE LightSpeed 64, GE Health-
are, Milwaukee, Wisconsin) after an overnight fast. Pa-
ients were instructed to avoid caffeine for at least 12 h and
ethylxanthine containing substances for 24 h.
Myocardial blood flow (MBF) was measured at rest and
uring peak hyperemia using 82Rubidium as a perfusion
racer. Following a scout CT scan (120 kVp, 10 mA) used
or proper patient positioning, a CT transmission scan was
cquired (140 kVp, 10 mA) for subsequent correction of
hoton attenuation. Beginning with the intravenous bolus
dministration of 82Rubidium (1,480 to 2,220 MBq), list
ode images were acquired for 7 min as previously described
12). Then, intravenous dipyridamole (0.142 mg/kg/min for 4
in, n 465 [52%]), adenosine (0.142 mg/kg/min for 4 min,
 50 [5%]), regadenoson (0.4 mg bolus, n 344 [38%]), or
obutamine (10 to 50 g/kg/min, n  42 [5%]) was infused.
t peak hyperemia, a second dose of 82Rubidium (1,480 to
,220 MBq) was injected and images were recorded in the
ame manner. A second CT transmission scan was acquired140 kVp, 10 mA) after vasodila-
or stress for attenuation correction
f the stress emission data. The
eart rate, systemic blood pressure,
nd 12-lead electrocardiogram
ere recorded at baseline and ev-
ry minute during and after the
nfusion of the stress agent. The
ate pressure product was calcu-
ated by multiplying heart rate and
ystolic blood pressure measured at
est and during peak hyperemia,
espectively.
CORONARY ARTERY CALCIUM CT
SCAN. After myocardial perfu-
ion imaging, all patients under-
ent CT scan for CAC scoring
uring breath-hold on the inte-
rated 64-slice multidetector CT
canner (collimation 64  0.625
m, gantry rotation time 350
s, effective temporal resolution
75 ms, 120 kV, 300 mA). CAC scans were performed
sing axial acquisition with prospective electrocardio-
raphic triggering at 70% of the R-R interval. Subse-
uently, 3-mm images were reconstructed using filtered
ack projection and a standard convolution kernel with a
12  512 matrix and a fixed 25-cm field of view. No
eta-blockers were administered and the average heart
ate during the study was 70 beats/min (range: 62 to 80
eats/min). Estimated radiation exposure for the inte-
rated PET/CT study was 5.46 mSv (range: 5.00 to 5.98
Sv).
esults
ET imaging data. LEFT VENTRICULAR SYSTOLIC
FUNCTION. Rest and stress left ventricular ejection fraction
ere calculated from gated myocardial perfusion images
sing commercially available software (Corridor4DM; In-
ia, Ann Arbor, Michigan). Left ventricular ejection frac-
ion reserve was considered present when LVEF increased
rom rest to stress.
QUANTITATIVE MYOCARDIAL BLOOD FLOW AND FLOW
RESERVE. Absolute MBF (in ml/g/min) was computed
from the dynamic rest and stress images using commercially
available software (Corridor4DM, Invia) and previously
validated methods (13). Automated factor analysis was used
to generate blood pool (arterial input function) and tissue
time-activity curves. Regional and global rest and peak
stress MBF were calculated by fitting the 82Rubidium
time-activity curves to a 2-compartment tracer kinetic
model as described previously (13). Per-patient global
Abbreviations
and Acronyms
CAC  coronary artery
calcium
CAD  coronary artery
disease
CI  confidence interval
CFR  coronary flow
reserve
CT  computed
tomography
MACE  major adverse
cardiac event(s)
MBF  myocardial blood
flow
MPI  myocardial perfusion
imaging
NRI  net reclassification
index
PET  positron emission
tomographycoronary flow reserve (CFR) was calculated as the ratio of
 cor
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Coronary Calcium, Vascular Function, and Prognosis May 21, 2013:2098–106absolute MBF at stress over rest for the entire left
ventricle. Quantitation of MBF was performed by 4
operators. Corrected MBF at rest was calculated by
dividing the MBF by the resting rate pressure product
Patient CharacteristicsTable 1 Patient Characteristics
Variable
All Patients
(n  901)
Demographics
Age, yrs 61.4 (53.6–69.7)
Male 288 (32.0%)
Hispanic 151 (16.8%)
Race
White 470 (52.2%)
Black 198 (22.0%)
Other/unknown 233 (25.9%)
Risk factors
BMI, kg/m2 30.2 (25.8–37.1)
BMI 30 kg/m2 463 (51.4%)
Hypertension 662 (73.5%)
Dyslipidemia 495 (54.9%)
Diabetes 275 (30.5%)
Family history of CAD 247 (27.4%)
Tobacco use 97 (10.8%)
Dialysis 38 (4.2%)
Clinical risk score, % 22.4 (10.3–46.3)
Medications
Aspirin 429 (47.6%)
-adrenergic blockers 403 (44.7%)
Cholesterol agents 417 (46.3%)
Insulin 106 (11.8%)
Oral hypoglycemic agents 102 (11.3%)
Calcium-channel blockers 180 (20.0%)
ACE inhibitors 301 (33.4%)
Nitrates 48 (5.3%)
Diuretics 269 (29.9%)
Indications
Chest pain 514 (57.1%)
Dyspnea 258 (28.6%)
Pre-operative 125 (13.9%)
Cardiovascular history
Cerebrovascular disease 30 (3.3%)
Peripheral vascular disease 33 (3.7%)
Stress protocol
Adenosine 50 (5.6%)
Dipyridamole 465 (51.2%)
Dobutamine 42 (4.7%)
Regadenoson 344 (38.2%)
Imaging parameters
Rest LVEF, % 63 (56–69)
Stress-induced LVEF drop 98 (10.9%)
Global CFR 1.96 (1.53–2.45)
Stress global MBF, ml/g/min 2.18 (1.64–2.88)
Rest global MBF, ml/g/min 1.08 (0.86–1.43)
CAC score (0/1–399/400) 44.6/40.0/15.4%
Values are median (interquartile range) or n (%). Patients whose left
considered to have positive stress-induced drop in LVEF. Coronary art
ACE angiotensin-converting enzyme; BMI body mass index; CAD
blood flow.and multiplying by 10,000. The intraclass correlation
coefficient for CFR among these 4 readers was 0.94 (95%
confidence interval [CI]: 0.88 to 0.98) (14), indicating
excellent reproducibility.
ardiac Events
(n  57)
No Cardiac Events
(n  844) p Value
3.2 (55.6–73.4) 61.4 (53.4–69.3) 0.005
24 (42.1%) 264 (31.3%) 0.090
9 (15.8%) 142 (16.8%) 0.84
0.11
27 (47.4%) 443 (52.5%)
18 (31.6%) 1,808 (21.3%)
12 (21.1%) 221 (26.2%)
3.2 (25.7–42.0) 30.2 (25.8–36.6) 0.035
34 (59.6%) 429 (50.8%) 0.19
48 (84.2%) 614 (72.8%) 0.058
40 (70.2%) 455 (53.9%) 0.017
29 (50.9%) 246 (29.2%) 0.0006
12 (21.1%) 235 (27.8%) 0.27
8 (14.0%) 89 (10.6%) 0.41
4 (7.0%) 34 (4.0%) 0.28
1.9 (21.9–67.6) 21.1 (9.6–45.4) 0.0001
31 (54.4%) 398 (47.2%) 0.29
38 (66.7%) 365 (43.3%) 0.0006
31 (54.4%) 386 (45.7%) 0.20
13 (22.8%) 93 (11.0%) 0.0075
10 (17.5%) 92 (10.9%) 0.13
19 (33.3%) 161 (19.1%) 0.0092
27 (47.4%) 274 (32.5%) 0.021
8 (14.0%) 40 (4.7%) 0.0025
22 (38.6%) 247 (29.3%) 0.14
29 (50.9%) 485 (57.5%) 0.33
26 (45.6%) 232 (27.5%) 0.0034
6 (10.5%) 119 (14.1%) 0.45
2 (3.5%) 28 (3.3%) 0.94
5 (8.8%) 28 (3.3%) 0.034
0.0004
2 (3.2%) 48 (5.7%)
45 (79.0%) 420 (49.8%)
1 (1.8%) 41 (4.9%)
9 (15.8%) 335 (39.7%)
60 (51–66) 63 (57–69) 0.025
9 (14.5%) 89 (10.6%) 0.39
.63 (1.23–2.00) 1.99 (1.56–2.47) 0.0001
.84 (1.25–2.42) 2.20 (1.66–2.92) 0.001
.13 (0.85–1.52) 1.08 (0.86–1.43) 0.92
.3/38.6/35.1% 45.9/40.1/14.1% 0.0001
lar ejection fraction (LVEF) at stress was less than that at rest were
ium (CAC) score was expressed as the proportions.
onary artery disease; CFR coronary flow reserve, MBFmyocardialC
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independent observers who were blinded to the patients’
clinical history, outcomes, and CFR results. Agatston
scores were computed with commercially available soft-
ware (Corridor4DM, INVIA) (10). Artery-specific scores
were summed across lesions identified in the left main,
left anterior descending, left circumflex, and right coro-
nary arteries to provide a total CAC score for each
patient.
Assessment of outcomes. The primary endpoint of the
tudy was a composite of major adverse cardiac events
MACE) such as cardiac death, myocardial infarction,
evascularization, and rehospitalization for heart failure.
scertainment of cause of death, nonfatal myocardial in-
arction, revascularization (90 days after PET/CT scan),
nd rehospitalization for heart failure were performed by
linded adjudication of 2 cardiologists. Vital status for all
atients was ascertained by careful integration of data from
he Social Security Death Index, the National Death Index,
nd the Partners Healthcare Research Patient Data Regis-
ry. Documentation of all other events was based on review
f the Partners Healthcare Research Patient Data Registry,
ailed questionnaires, and telephone interviews with pa-
ients or their next of kin. Myocardial infarction was defined
ccording to American College of Cardiology/European
ociety of Cardiology criteria (15). Cardiac death was
efined as death of any cause including a fatal myocardial
nfarction, sudden cardiac death, or heart failure, which was
djudicated by review of hospital records, autopsy records,
nd death certificates from the National Death Index.
tatistical analysis. Patient demographics and baseline char-
cteristics were summarized as medians and interquartile
anges or means and standard deviation for continuous vari-
bles, as appropriate based on normality, and frequencies for
ichotomous and ordinal variables. Statistical significance was
ssessed using Student t tests or Wilcoxon tests for normal and
onnormal continuous data and with Fischer exact or chi-
quare tests for dichotomous and ordinal variables. Correlation
etween continuous CFR and continuous CAC score was
ssessed using linear regression analysis. Two-sided p values
Quantitative Myocardial Perfusion and CACTable 2 Quantitative Myocardial Perfusion and CAC
Quantitative
Myocardial
Perfusion
CAC
0
(n  402)
1–399
(n  360)
>400
(n  139) p Value
Rest MBF,
ml/g/min
1.20 0.51 1.19 0.45 1.15 0.50 0.62
Corrected rest
MBF, ml/
g/min
1.32 0.84 1.30 0.68 1.29 0.82 0.87
Peak MBF,
ml/g/min
2.47 1.06 2.30 0.89 2.08 0.99 0.0002
Coronary flow
reserve
2.15 0.72 2.02 0.65 1.88 0.64 0.0001
Values are mean SD. Statistical significance was assessed for the linear trend across categories
of coronary calcium.
CAC  coronary artery calcium; MBF  myocardial blood flow.Figure 1 Relationship Between CFR
and Extent of Coronary Calcification
Relative frequency of decreased coronary vascular function (i.e., coronary flow
reserve [CFR]  2.0) by extent and severity of coronary artery calcification
(CAC) (A). Coronary flow reserve across coronary artery calcium (CAC) score
categories (0, 1 to 399, and 400) (B). Dotted line reflects the median value
of the entire population (CFR  2.0). Correlation between CFR and coronary
artery calcium (C). The dotted line reflects the 95% confidence intervals.
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Coronary Calcium, Vascular Function, and Prognosis May 21, 2013:2098–1060.05 were considered significant. All statistical analyses were
performed using SAS 9.2 (SAS Institute Inc., Cary, North
Carolina).
MULTIVARIABLE MODELING. Cox proportional hazards
models were used to assess the impact of CAC, CFR, and the
2 combined on MACE after adjustment for the effects of
Duke clinical risk score, which integrates age, sex, symptoms,
electrocardiographic findings, and coronary risk factors (11).
Log transformations of the Duke clinical risk score, CFR, and
CAC  1 were used to accommodate the rightward skew of
the data and to reduce heteroscedasticity. A series of models
were developed starting with 1 containing only Duke clinical
risk score. Then ln(CAC  1) and CFR (as continuous
variables) and the 2 combined were sequentially incorporated.
Ln(CAC  1) as a continuous variable was selected over a
categorical representation due to improved model fit with
fewer parameters. At each stage the models were carefully
examined for the validity of the proportional hazards assump-
tion and additive value. A sensitivity analysis was conducted to
evaluate the impact of incomplete follow-up (Online Appendix).
Survival was plotted using direct adjusted MACE probabil-
ities from the Cox survival model (16). Poisson regression
was used to compute adjusted annualized event rates.
ASSESSMENT OF INCREMENTAL VALUE. Incremental prog-
nostic value of CAC, CFR, and the 2 combined was
assessed with the likelihood ratio test to assess the improved
fit of a Cox model containing CAC, CFR, and the 2
combined to 1 with clinical risk score. The c-index was
calculated for each model (17) and comparisons were made
with the method of Antolini et al. (18). The potential
impact of CAC, CFR, and the 2 combined for
the assessment of cardiac risk on clinical management was
assessed by net reclassification improvement at 3 years using
estimated annual rates of MACE of 2%, 2 to 6%, and
6% to define categories of low, intermediate, and high
risk, respectively (19,20). Because cardiac death accounted
for only half of the MACE in our cohort of patients with
suspected coronary artery disease, we used thresholds that
are twice as high as the cutpoints proposed for stratifica-
Cause of Death and Cardiac Events by Groups of CAC and CFRTable 3 Cause of Death and Cardiac Events by Groups of CAC
All
(n  901)
C
0
(n  402)
1–399
(n  360)
Major adverse cardiac events 57 (6.3%) 15 (3.7%) 22 (6.1%)
Death
Cardiac 12 (1.3%) 2 (0.5%) 7 (1.9%)
Noncardiac 18 (2.0%) 6 (1.5%) 8 (2.2%)
Any cause 30 (3.3%) 8 (2.0%) 15 (4.2%)
Myocardial infarction 21 (2.3%) 6 (1.5%) 6 (1.7%)
Late revascularization 7 (0.8%) 0 (0%) 2 (0.6%)
Heart failure admission 24 (2.7%) 9 (2.2%) 9 (2.5%)
Values are n (%). Major adverse cardiac events consist of cardiac death, nonfatal myocardial inf
Cochran-Armitage trend test (coronary artery calcium [CAC]) and Fisher exact test (coronary flowtion of patients at low and high risk of cardiac death (1% rand 3%, respectively) in ACC/AHA stable angina guide-
lines (21,22).
Results
Patient characteristics. A total of 901 consecutive patients
met inclusion criteria during the study period and were
followed for a median of 1.53 years (interquartile range: 0.77 to
2.44 years). Complete follow-up, defined as 90 days or
hrough the end of the study period, was obtained for 92.1% of
atients. Baseline characteristics of the study cohort are sum-
arized in Table 1. Two-thirds of the patients were women.
oronary risk factors were prevalent in this cohort. Patients
ho experienced MACE were older, more likely to have
yspnea at presentation, had a higher Duke clinical risk score,
ad a lower left ventricular ejection fraction, had a lower peak
yocardial blood flow and flow reserve, and a higher CAC
core.
yocardial blood flow and CAC score. In univariate
nalysis, rest MBF was comparable across categories of CAC
core. In contrast, peak MBF and CFR showed a modest but
tatistically significant stepwise decline with increasing levels of
AC score (Table 2). The relative frequency of decreased
FR increased with increasing CAC scores (Fig. 1A). How-
ver, there was wide variability in abnormal coronary vasodi-
ator function in each level of CAC score (Figs. 1B and 1C).
atient outcomes. Table 3 summarizes the patients’ clin-
cal outcomes by CAC score and CFR. Overall, 57 patients
6.3%) experienced MACE. The frequency of adverse
ardiac events was higher with increasing CAC score and in
he presence of reduced CFR.
Unadjusted Kaplan-Meier curves show that patients with
FR 2.0, the median value for this cohort, had a
ignificantly higher event rate than those with CFR 2.0
p  0.0001). Similarly, patients with CAC 400 had a
igher event rate than those with lower CAC scores (p 
.002). After adjusting for clinical risk score, the similar
rends were observed (Figs. 2A and 2B). Unadjusted annual
ACE rate increased with increasing levels of coronary
alcium (2.8, 4.5, and 8.9%/year, p  0.005) and with
FR
CFR
>400
(n  139) p Value
>2.0
(n  430)
<2.0
(n  471) p Value
20 (14.4%) 0.0001 14 (3.3%) 43 (9.1%) 0.0003
3 (2.2%) 0.07 1 (0.2%) 11 (2.3%) 0.0066
4 (2.9%) 0.28 6 (1.4%) 12 (2.6%) 0.21
7 (5.0%) 0.04 7 (1.6%) 23 (4.9%) 0.0083
9 (6.5%) 0.005 5 (1.2%) 16 (3.4%) 0.028
5 (3.6%) 0.0002 1 (0.2%) 6 (1.3%) 0.13
6 (4.3%) 0.25 8 (1.9%) 16 (3.4%) 0.21
, late revascularization, and heart failure admission. Statistical significance was assessed using
[CFR]).and C
ACeduced CFR (2.3 vs. 6.6%/year, p  0.002). The
2103JACC Vol. 61, No. 20, 2013 Naya et al.
May 21, 2013:2098–106 Coronary Calcium, Vascular Function, and Prognosisobservation of increased MACE rates with CFR 2.0
compared with 2.0 remained after adjustment for
clinical risk (1.9 vs. 5.5%/year, p  0.0007). In contrast,
after adjustment for clinical risk, the association between
CAC and MACE rates was only of borderline signifi-
cance (3.1%, 3.4%, and 6.2%/year for CAC of 0, 1 to 399,
and 400, respectively; p  0.09). Comparison of
MACE across CAC in 2 categories of 400 and 400
revealed a risk-adjusted hazard ratio of 1.8 (95% CI: 1.0
to 3.2) with borderline significant (p  0.04).
When considering both CAC and CFR, annual MACE
rates were increased in the presence of impaired CFR at any
level of CAC score (p  0.002), including among patients
with a CAC score of 0 (risk ratio: 3.6; 95% CI: 1.2 to 11.4;
p  0.03). After adjustment for clinical risk score, similar
relationships between CFR and MACE were demonstrated
(Fig. 3), although the relationship between CAC and
MACE rates was no longer significant.
Multivariable modeling. A series of multivariable models
Figure 2 Event-Free Survival by CFR and Extent of
Coronary Calcification
Adjusted survival probabilities by coronary flow reserve (CFR) (A) and catego-
ries of coronary artery calcium (CAC) score (B). After adjusting for clinical risk,
patients with CFR 2.0 had a significantly higher event rate than those with
CFR 2.0 (A). Likewise, patients with CAC 400 had a higher event rate than
those with lower CAC score (B). CI  confidence interval; HR  hazard ratio;
MACE  major adverse cardiac event(s).were constructed to assess the incremental value of CFR afteradjustment for clinical risk (Table 4). These models demon-
strated that CFR added incremental prognostic information
over the pre-imaging model with improvements in global
chi-square test, Akaike information criterion, and c-index.
Addition of CAC to clinical risk resulted in modest improve-
ment in the model fit, which was significant by global chi-
square test but not Akaike information criterion, and did not
improve the c-index, a measure of risk discrimination. The 2
measures combined added incremental prognostic information
over clinical risk and CAC alone but not over clinical risk and
CFR alone (Table 4). Addition of a CAC*CFR interaction
term to the final model (clinical risk, CAC, and CFR) did not
improve global chi-square test (p  0.28). In addition to the
primary analysis using CAC and CFR as log-transformed
continuous predictors, we also performed additional analyses of
the data using 2 binary thresholds of CAC score: CAC 0
versus any CAC (CAC 1), and CAC 400 versus 400,
and 3 categories of CAC score (0, 1 to 399, and 400). We
found that neither a binary threshold of CAC1 (vs. CAC
0) nor the 3 categories of CAC (0, 1 to 399, 400) signifi-
cantly improved model fit beyond clinical risk alone. However,
a binary threshold of CAC 400 (vs. CAC 400) added
incremental prognostic value to clinical risk alone but not to
clinical risk  CFR (Online Tables 1 and 2). In order to
evaluate the robustness of the results given 7.9% of patients had
incomplete follow-up, a sensitivity analysis was also performed
and yielded nearly identical results (Online Table 3).
Reclassification and discrimination. In the entire cohort,
24%, 43.6%, and 45.7% of patients were reclassified by
CAC, CFR, and the combination of CAC and CFR,
respectively (Online Table 4). Accounting for incorrect
reclassifications, addition of CAC did not result in significant
favorable net reclassification (net reclassification index [NRI]
[2.6%]: 0.141; 95% CI:0.003 to 0.286) (Online Table 5). In
Figure 3 Annualized MACE by Extent of
Coronary Calcification and Flow Reserve
Risk-adjusted annual MACE rates by CFR (below and above 2.0) and CAC score
(0, 1 to 399, and 400) categories. MACE were greatest among patients with
high CAC and decreased CFR. Interestingly, the rate of MACE increased in the
presence of impaired CFR even among patients with CAC  0 although CAC
was not significantly associated with increased MACE rates. Abbreviations as
in Figure 2.
Multivariable Survival AnalysisTable 4 Multivariable Survival Analysis
Model
Model 1: Clinical Risk Score* Model 2: Clinical Risk Score  CAC Model 3: Clinical Risk Score  CFR Model 5: Clinical Risk Score  CAC  CFR
Fit
Statistic HR p Value
Fit
Statistic HR p Value
Fit
Statistic HR p Value
Fit
Statistic HR p Value
Global chi-square
test
19.0 ref 24.4 0.02 44.5 0.0001 46.7 0.0001 (vs. model 1)
0.0001 (vs. model 2)
0.14 (vs. model 3)
AIC 588.6 ref 585.1 0.06 565.1 0.0001 564.9 0.0001 (vs. model 1)
0.0001 (vs. model 2)
0.63 (vs. model 3)
c-index 0.632 (0.5500.714) ref 0.644 (0.5610.728) 0.58 0.719 (0.6470.791) 0.004 0.719 (0.6510.788) 0.002 (vs. model 1)
0.01 (vs. model 2)
0.97 (vs. model 3)
Duke clinical risk
score (per 10%)
1.06 (1.031.10) 0.0001 1.05 (1.021.08) 0.003 1.06 (1.031.10) 0.0002 1.05 (1.021.09) 0.004
CAC (per 2-fold
increase)
1.09 (1.011.17) 0.02 1.06 (0.981.13) 0.14
CFR (per 10%
increase)
0.82 (0.760.89) 0.0001 0.83 (0.760.89) 0.0001
A log transformation of the Duke clinical risk score, CFR and CAC  1 were used for the analyses to adjust for the rightward skew of the data and to reduce heteroscedasticity. Global chi-square test indicated likelihood ratio chi-square statistic for the entire model. p Values
for model fit statistics (i.e., global chi-square test, AIC and c-index) are for comparisons with model 1, unless specified. C-indices are calculated for 3-year event date. *The components to calculate Duke clinical risk score consist of age, sex, typical angina, atypical angina,
history of myocardial infarction, ECG Q-wave, ECG ST-T wave changes, smoking, dyslipidemia, diabetes, age by sex, history of myocardial infarction by electrocardiogram Q-wave, age by sex, age by dyslipidemia, and sex by smoking (interaction) (11).
AIC  Akaike information criterion; other abbreviations as in Table 3.
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(NRI [2.6%]: 0.280; 95% CI: 0.048 to 0.502).
Among the 51% of patients at intermediate pre-test risk
based on the Duke clinical risk score, addition of CFR
resulted in highly effective risk reclassification (NRI [2.6%]:
0.569; 95% CI: 0.326 to 0.807). In contrast, addition of
CAC did not result in significant reclassification improve-
ment (NRI [2.6%]: 0.168; 95% CI: 0.028 to 0.394).
Discussion
We found that among symptomatic patients without
obstructive CAD, although both the extent of coronary
calcium deposits and the presence of coronary vascular
dysfunction are associated with increased risk of adverse
cardiac events, after adjustment for clinical risk, only
coronary vascular dysfunction improved risk assessment.
In keeping with prior studies, the total burden of coro-
nary calcium deposits was only modestly associated with
impaired vascular function (23). More importantly, we
observed that for any level of CAC score, the presence of
abnormal CFR (reflecting the effect of diffuse atheroscle-
rosis, as well as epicardial and microvascular dysfunction)
was consistently associated with a higher rate of adverse
cardiac events, even after adjusting for clinical risk.
Indeed, even among patients with no CAC, impaired
CFR was associated with higher rates of MACE (1.3%
vs. 4.7%, p  0.03). CFR helped reclassify risk in 44% of
he entire cohort, with large net improvement in risk
lassification among those at intermediate clinical risk. In
ontrast, CAC did not result in improved risk assessment
fter accounting for clinical risk in these symptomatic
atients with a high burden of risk factors. These results
uggest that coronary vascular dysfunction, the earliest
arker of atherosclerosis may be a more powerful and
niversal marker of risk of adverse cardiac outcomes.
We observed a wide dispersion of CFR values in each
AC score category. Although there was a stepwise increase
n the frequency of decreased CFR with increasing CAC
cores, this relationship was modest (Fig. 1). In our cohort
f patients without obstructive CAD (all patients had
ormal PET scans), measures of coronary vasodilator func-
ion reflect the integrated effects of diffuse atherosclerosis
nd endothelial dysfunction. Consequently, CFR is a useful
urrogate marker of disease activity in the coronary circula-
ion that may reflect active pathophysiologic changes, which
re more readily reversible with medical and lifestyle inter-
entions than coronary calcifications. The scatter of coro-
ary vasodilator reserve values in each CAC score category
uggests that calcium deposits are not a complete reflection
f overall disease activity within the coronary circulation.
his is consistent with prior studies in asymptomatic cohorts
24,25). In a recent meta-analysis, circulating inflammatory
iomarkers (including C-reactive protein, interleukin-6, fibrin-
gen, matrix metalloproteinase-9, monocyte chemoattractant
rotein-1, tumor necrosis factor-alpha, and others) were foundo have only a weak association with the burden of coronary
rtery calcifications (24). Together, these findings may help
xplain the relatively low numbers of coronary events even
mong patients with high CAC scores (8,26). Our data
upport the hypothesis that direct measures of coronary
asodilator function (more closely reflecting disease activity)
ay be more powerful measures of CAD risk than simply
he total burden of calcified atherosclerosis.
tudy limitations. First, this study was performed in a
ingle referral center and may reflect referral bias. However,
his cohort may more closely reflect patients with suspected
oronary disease seen in practice than those selected for
rospective studies. Second, physicians were aware of the
AC, but not of CFR, which may attenuate the predictive
alue of CAC for cardiac events due to resultant changes in
edical therapy. Third, the number of events was limited
nd the follow-up period relatively short. Fourth, the
ET/CT studies were all performed for clinical indications,
argely for evaluation of symptoms. As such the relative
rognostic value of CAC and CFR in asymptomatic pa-
ients was not assessed in the present study. Fifth, abnormal
FR, while most likely representing microvascular dysfunc-
ion or diffuse atherosclerosis in our study because all
atients had normal MPI images, could also be a marker for
picardial obstructive disease in rare cases of balanced
eduction in blood flow.
onclusions
oronary vasomotor dysfunction, the earliest manifestation of
therosclerosis, may be a more powerful marker of cardiac risk
han the total burden of calcified atherosclerosis, a late marker
f plaque rupture and healing, among symptomatic patients
ithout obstructive CAD. For any level of severity of coronary
rtery calcification, impaired CFR consistently identified pa-
ients at higher short-term risk of adverse cardiac events. These
esults suggest that direct measures of coronary vascular func-
ion, reflecting disease activity in the coronary circulation, may
mprove phenotypic characterization of atherosclerosis and
esult in enhanced risk stratification and prediction of cardio-
ascular events among symptomatic patients.
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APPENDIX
For expanded Methods and Results sections as well as additional tables,
please see the online version of this article.
